New FDA-Approved Treatment Provides More Options For Patients With Most Common Type Of Kidney Cancer

Sunday, March 1, 2009

With Most Common Type Of Kidney Cancer (NAPSA)—According to a recent study published in the American Journal of Epidemiology, the number of newly diagnosed cases of renal cell carci- noma, the most common form of kidney cancer, has been increasing over the past several decades. Fewer than 10 percent of latestage kidney cancer patients will live five years; however, people battling metastatic renal cell carcinoma have hope for tomorrow thanks to a newly approved medicine that works differently than other available treatments. In July 2009, the U.S. Food and Drug Administration approved Avastin (bevacizumab) plus interferon alfa to treat people with metastatic renalcell carcinoma. This approval is based on data from a Phase ITI study (AVOREN) that showed patients who received Avastin plus interferon alfa had a 67 percent improvement in the time they lived without the disease worsening (progression-free survival or PFS), compared to those who received interferon alfa alone (hazard ratio=0.60, 95 CI=0.49, 0.72, p

--- PHOTOS ---

File: 20190731-152723-20190731-152719-77703.pdf.jpg

--- FILES ---

File: 20190731-152719-77703.pdf